枫蓼肠胃康胶囊联合标准四联疗法治疗Hp阳性慢性胃炎临床研究  

Clinical Study on Fengliao Changweikang Capsules Combined with Standard Quadruple Therapy for Hp Positive Chronic Gastritis

作　　者：张燕霞 毕玉珍 ZHANG Yanxia;BI Yuzhen(The First People's Hospital of Chun'an County,Chun'an Zhejiang 311700,China)

机构地区：[1]淳安县第一人民医院,浙江淳安311700

出　　处：《新中医》2024年第19期71-75,共5页New Chinese Medicine

摘　　要：目的:观察枫蓼肠胃康胶囊联合标准四联疗法治疗幽门螺杆菌(Hp)阳性慢性胃炎的疗效及对胃肠功能和氧化应激水平的影响。方法:选取112例Hp阳性慢性胃炎患者进行前瞻性研究,所有患者按随机数字表法分为联合组和对照组各56例。对照组给予标准四联疗法治疗,联合组在对照组基础上联合枫蓼肠胃康胶囊治疗,共治疗1个月。比较2组Hp转阴率、临床疗效及不良反应发生情况;比较2组治疗前后氧化应激指标[血清谷胱甘肽(GSH-PX)、超氧化物歧化酶(SOD)及丙二醛(MDA)]、血清炎症因子[白细胞介素-4(IL-4)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、核转录因子-κB(NF-κB)以及白细胞介素-6(IL-6)]、胃肠功能指标[(胃蛋白酶原Ⅱ、胃蛋白酶原Ⅰ、胃泌素)]水平。结果:治疗后,联合组总有效率96.43%,高于对照组76.79%(P<0.05)。联合组Hp转阴率85.71%,高于对照组66.07%(P<0.05)。治疗后,2组血清MDA、IL-4、IL-6、IL-8、NF-κB、TNF-α及胃蛋白酶原Ⅱ、胃蛋白酶原Ⅰ及胃泌素水平均较治疗前降低(P<0.05),SOD、GSH-PX、IL-10水平升高(P<0.05);联合组MDA、IL-4、IL-6、IL-8、NF-κB、TNF-α及胃蛋白酶原Ⅱ、胃蛋白酶原Ⅰ及胃泌素水平低于对照组(P<0.05),SOD、GSH-PX、IL-10水平高于对照组(P<0.05)。联合组不良反应发生率8.93%,低于对照组23.21%(P<0.05)。结论:枫蓼肠胃康胶囊联合标准四联疗法治疗Hp阳性慢性胃炎疗效显著,可有效提高患者Hp转阴率,抑制氧化应激损伤和炎症反应,改善胃肠功能。Objective:To observe the therapeutic effect of Fengliao Changweikang Capsules combined with standard quadruple therapy in the treatment of Helicobacter pylori(Hp)positive chronic gastritis,as well as its impact on gastrointestinal function and oxidative stress levels.Methods:A prospective study was conducted on 112 patients with Hp positive chronic gastritis.All patients were randomly divided into the combination group and the control group,with 56 cases in each group,using a random number table method.The control group was treated with standard quadruple therapy,and the combination group was treated with Fengliao Changweikang Capsules in combination with the treatment of the control group.Both groups were treated for a total of one month.Compared the Hp conversion negative rate,clinical effects,and incidence of adverse reactions between the two groups,and compared the levels of oxidative stress indicators[serum glutathione peroxidase(GSH-PX),superoxide dismutase(SOD),and malondialdehyde(MDA)],serum inflammatory indicators[interleukin-4(IL-4),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8),interleukin-10(IL-10),nuclear factor-κB(NF-κB),and interleukin-6(IL-6)],and gastrointestinal function indicators(pepsinogenⅡ,pepsinogenⅠand gastrin)before and after treatment.Results:After treatment,the total effective rate was 96.43%in the combination group,which was higher than the control group's 76.79%(P<0.05).The Hp conversion negative rate was 85.71%in the combination group,which was higher than the control group's 66.07%(P<0.05).After treatment,the serum MDA,IL-4,IL-6,IL-8,NF-κB,TNF-α,pepsinogenⅠ,pepsinogenⅡand gastrin levels in the two groups were decreased when compared with those before treatment(P<0.05),SOD,GSH-PX and IL-10 levels were increased(P<0.05).The levels of MDA,IL-4,IL-6,IL-8,NF-κB,TNF-α,pepsinogenⅠ,pepsinogenⅡand gastrin levels in combination group were lower than those in control group(P<0.05),and the levels of SOD,GSH-PX and IL-10 in combination group were higher than those in cont

关 键 词：慢性胃炎 幽门螺杆菌 四联疗法 枫蓼肠胃康胶囊 氧化应激 胃肠功能 

分 类 号：R573.3[医药卫生—消化系统]